Sign in
TRAW Stock Price, Chart, Stats & News
Traws Pharma, Inc.
Save
7.77M
Market cap
–
Current P/E
–
Forward P/E
TRAW chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.93% |
Operating margin | -350.72% |
Pretax margin | -336.56% |
Net margin | -326.16% |
Effective tax rate | – |
ROA | -58.25% |
ROE | 77.88% |
D/E | – |
Interest coverage ratio | – |
TRAW valuation
P/E | – |
P/S | 3.01x |
P/B | 1.24x |
P/CF | -1.02x |
P/FCF | -0.84x |
P/OCF | -1.02x |
PEG | -0.03x |
EV multiple | -1.96x |
About
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza.
Similar securities
Based on sector and market capitalization
Report issue